ClinicalTrials.gg
RecruitingNCT07680998TRACEUpdated Jul 8, 2026

Performance and Safety of the ANTALGEEK® Thess Monitoring Medical Device in the Outpatient Management of Acute Pain and Postoperative Recovery

An interventional study of Post-operative follow-up using the Thess Telemonitoring device in conjunction with the ANTALGEEK® protocol in Post Operative Pain and Chronic Pain, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by Centre Hospitalier Universitaire de Nīmes · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Registered 6 months after the study started (first participant enrolled Dec 2025, registered Jun 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Pain, Postoperative with a site in France — 18 open to participants now, 21 under way, 3 of them phase 3. Pain, Postoperative · France.

Planned enrollment
35th of 83
150 · median 140
Started
2025
with 4 others
No phase
41 of 103
11 open now
Primary completion
2026-08
later than 3 of 20 live
Registered
94th of 103
by date

Among the 103 studies in Pain, Postoperative with a site in France, this one is the 35th largest by planned enrollment of the 83 interventional ones that give a count, is one of 5 that started in 2025, is one of 41 with no phase, reaches primary completion later than 3 of the 20 other live ones, and was the 94th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

18 of the 103 studies in Pain, Postoperative with a site in France are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Pain, Postoperative with a site in France, or all of them as a file.
02

Study summary

Acute postoperative pain (APOP) is a major public health problem, affecting nearly 10 million patients in France each year. Effective analgesic therapy in the first postoperative week is a key factor in reducing early postoperative morbidity and mortality. Poorly controlled APOP is a major risk factor for chronic postoperative pain. In France today, more and more patients undergo surgical procedures as outpatients. The challenge is to manage postoperative pain in the homes of patients who have undergone increasingly complex surgical procedures, either after outpatient surgery or after a prompt return home as part of an Enhanced Recovery After Surgery (ERAS) protocol. In outpatient surgery, postoperative pain management requires new strategies and/or organizational approaches to ensure high-quality pain management from the very start. The principle of analgesia for acute postoperative pain recommends: i) routine, fixed-schedule maintenance therapy; and ii) rescue therapy if maintenance therapy is insufficient, based on pain titration, using mild or strong oral opioids. Postoperative pain is the primary focus of postoperative care but the goal is also to improve postoperative recovery and enhance the patient's overall care. To date, there are no medical telemonitoring devices to support the patient in properly taking their analgesics based on multiple-daily assessments of the efficacy and tolerability of the analgesic treatment, enabling systematic postoperative screening for early and late warning signs of the risk of chronic pain. The Thess Monitoring device, which implements the ANTALGEEK® protocol, (TMA) was developed to optimize the efficiency of outpatient management of acute postoperative pain. It improves patients' adherence to maintenance treatment with adaptive, personalized control of analgesia through better use of opioid rescue therapy, and the reduction of adverse effects associated with improper opioid use (under- or over-dosing). The aim is to ensure optimal pain resolution and improve early and late postoperative recovery during the first postoperative week. The TMA system enables remote monitoring of the efficacy and tolerability of analgesic treatment, as well as early and late warning signs of the risk of chronic pain. By measuring pain scores daily during the first postoperative week, it identifies patients with a suboptimal pain trajectory who are at high risk of developing persistent pain beyond the third month. It also assesses warning signs of the risk of chronic pain (neuropathic pain, persistent opioid use) at intervals following the procedure (Day 8, Month 1, Month 2, Month 3). Improving the patient care pathway via the TMA system should make it possible to better coordinate postoperative follow-up between hospital-based and community-based care.

Read the detailed description

The problem of acute postoperative pain (APOP) is a major public health problem, affecting nearly 10 million patients in France each year and potentially leading to numerous complications when inadequately managed. In the postoperative period, the implementation of effective analgesic therapy is a key factor in reducing early postoperative morbidity and mortality. Furthermore, poorly controlled PPS is one of the major risk factors for the development of chronic postoperative pain (CPOP). Optimizing analgesic medication to prevent an abnormal pain trajectory during the first postoperative week is a key strategy for preventing chronic postoperative pain.

Today, within the French healthcare system, an increasing number of patients undergo surgical procedures performed on an outpatient basis. The big challenge is to manage postoperative pain in the homes of patients who have undergone increasingly complex surgical procedures, either following outpatient surgery or after an early return home as part of an Enhanced Recovery After Surgery (ERAS) protocol.

In outpatient surgery, improving postoperative pain management requires the implementation of new strategies and/or organizational approaches to ensure a high-quality pain management pathway from the very beginning.

The principle of analgesia for acute postoperative pain recommends a combination of: i) routine, fixed-schedule maintenance therapy; and ii) rescue therapy-if maintenance therapy is insufficient-based on the principle of pain titration, using oral opioids (mild or strong). While postoperative pain remains the primary focus of postoperative care, the goal is also to improve postoperative recovery more broadly and thereby enhance the patient's overall care.

The assessment of postoperative recovery in outpatient surgery patients using a medical telemonitoring device is associated with a reduction in discomfort caused by various postoperative symptoms, including postoperative pain. However, to date, there is no medical telemonitoring device that both supports the patient in properly taking their analgesics based on multiple-daily assessments of the efficacy and tolerability of the analgesic treatment, and enables systematic postoperative screening for early and late warning signs of the risk of chronic pain.

To this end, the Thess Monitoring medical telemonitoring device (which implements the ANTALGEEK® protocol) (TMA) was developed. It is a tool for continuous therapeutic support and postoperative telemonitoring designed to optimize the efficiency of outpatient management of acute postoperative pain in patients by improving adherence to maintenance therapy, adaptive and personalized control of analgesia through better use of opioid rescue therapy, and the reduction of adverse effects associated with improper opioid use (under- or over-dosing), with the goal of ensuring optimal pain resolution and improved early and late postoperative recovery during the first postoperative week (Baseline-Day 7). To achieve this, the TMA system enables remote monitoring of the efficacy and tolerability of analgesic treatment, as well as early and late warning signs of the risk of chronic pain: identify, through daily measurement of pain scores during the first postoperative week, patients with a suboptimal pain trajectory who are at high risk of developing persistent postoperative pain beyond the third month; assess warning signs of the risk of chronic pain (neuropathic pain, persistent opioid use) at intervals following the procedure (Day 8, Month 1, Month 2, Month 3).

Improving the patient care pathway through the TMA system should thus make it possible to better coordinate postoperative follow-up between hospital-based and community-based care.

In this initial proof-of-concept study, the investigators aim to evaluate the performance and safety of the TMA medical device in the outpatient management of acute pain during the first postoperative week, as well as its impact on postoperative recovery and on reducing the risk of pain becoming chronic by the third postoperative month.

03

Conditions studied

  • Post Operative Pain
  • Chronic Pain

Keywords

  • Post Operative Pain
  • Pain Management
  • Monitoring
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients eligible for outpatient surgery.
  • Patients undergoing surgery likely to result in moderate to severe pain.
  • Patients available for a 3-month follow-up.
  • Patients who have provided their free and .
  • Patients who have signed the consent form.
  • Patients enrolled in or covered by a health insurance plan.

Exclusion criteria

Exclusion Criteria:

  • Patients participating in an interventional RIPH study involving a drug or classified as Category 1.
  • Patients in an exclusion period determined by another study.
  • Patients under judicial protection, guardianship, or conservatorship.
  • Patients unable to express consent.
  • Patient for whom it is impossible to provide informed information.
  • Pregnant, laboring, or breastfeeding patients.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • No intervention
    Postoperative pain management : standard care

    Patients receiving standard postoperative analgesic care

  • Experimental
    Postoperative pain management using the Thess telemonitoring device

    Patients being monitored with the Thess Monitoring medical telemonitoring device in conjunction with the ANTALGEEK® protocol

    Device: Post-operative follow-up using the Thess Telemonitoring device in conjunction with the ANTALGEEK® protocol

Interventions

  • DevicePost-operative follow-up using the Thess Telemonitoring device in conjunction with the ANTALGEEK® protocol

    The Thess monitoring medical device (Thess Corp., Montpellier) uses the remote ANTALGEEK® telemonitoring protocol to manage pain in outpatients who have had surgery causing moderate-to-severe pain. It digitalizes and optimizes acute postoperative pain management at home by improving adherence to maintenance therapy, with adaptive, tailored control of analgesia through better use of opioid rescue therapy to reduce the adverse effects of opioid misuse and ensures optimal pain resolution and postoperative recovery during the first week. The ANTALGEEK decision-making algorithm and a medical telemonitoring protocol help patients follow their pain medication regimen, monitoring them in postoperative Week 1, based on the preoperative prescription, data on the patient's adherence to treatment, its efficacy and tolerability.

06

What researchers measure

Primary outcomes

  1. Performance of the TMA® medical device (TMA group) according to the QoR-15 questionnaire score in the experimental group

    The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90

    Time frame: Day 2

  2. Performance of the TMA® medical device (TMA group) according to the QoR-15 questionnaire score in the standard care (control) group.

    The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90

    Time frame: Day 2

Secondary outcomes

  1. Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the experimental group

    The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90

    Time frame: Day 1, before the intervention

  2. Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the experimental group

    The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90

    Time frame: Day 1, after the intervention

  3. Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the experimental group

    The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90

    Time frame: Day 7

  4. Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the standard care (control) group

    The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90

    Time frame: Day 1, before the intervention

  5. Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the standard care (control) group

    The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90

    Time frame: Day 1, after the intervention

  6. Quality of postoperative recovery (QoR15) during the early and late phases of recovery in the standard care (control) group

    The QoR-15 (quality of recovery) questionnaire comprises 15 items assessing different aspects of a patient's recovery : symptoms, functional status, and emotional well-being. The 15 items are grouped into five domains: Physical Comfort (symptoms like nausea, vomiting, and general discomfort), Emotional State (feelings such as anxiety, depression, or general well-being), Physical Independence (the patient's ability to look after themselves, such as mobility and self-care), Psychological Support (feelings of support and reassurance) Pain (the level of pain experienced by the patient). Each item in the QoR-15 is scored on an 11-point numerical scale ranging from 0 (none of the time/worst outcome) to 10 (all of the time/best outcome). The sum of the scores for each of the 15 items results in a score ranging from 0 (very poor recovery) to 150 (excellent quality of recovery). Excellent: QoR-15 score \> 135, Good: QoR-15 score between 122 and 135 (inclusive), Moderate: QoR-15 score between 90

    Time frame: Day 7

  7. Pain progression in the experimental group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 1

  8. Pain progression in the experimental group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 2

  9. Pain progression in the experimental group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 3

  10. Pain progression in the experimental group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 4

  11. Pain progression in the experimental group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 5

  12. Pain progression in the experimental group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 6

  13. Pain progression in the experimental group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 7

  14. Pain progression in the experimental group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Month 1

  15. Pain progression in the experimental group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Month 2

  16. Pain progression in the experimental group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Month 3

  17. Pain progression in the in the standard care (control) group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 1

  18. Pain progression in the in the standard care (control) group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 2

  19. Pain progression in the in the standard care (control) group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 3

  20. Pain progression in the in the standard care (control) group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 4

  21. Pain progression in the in the standard care (control) group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 5

  22. Pain progression in the in the standard care (control) group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 6

  23. Pain progression in the in the standard care (control) group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Day 7

  24. Pain progression in the in the standard care (control) group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Month 1

  25. Pain progression in the in the standard care (control) group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Month 2

  26. Pain progression in the in the standard care (control) group

    Average pain score over 24 hours according to the Visual Analog Scale (0 -10)

    Time frame: Month 3

  27. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group

    Patient's declaration in the Thess Monitoring Application

    Time frame: Baseline

  28. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group

    Phone call from the patient

    Time frame: Baseline

  29. rate of adherence to the standard pain management regimen (non-opioid analgesics) in the in the standard care (control) group

    Phone call from the patient

    Time frame: Day 1

  30. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group

    Patient's declaration in the Thess Monitoring Application

    Time frame: Day 2

  31. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group

    Phone call from the patient

    Time frame: Day 2

  32. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group

    Patient's declaration in the Thess Monitoring Application

    Time frame: Day 3

  33. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group

    Phone call from the patient

    Time frame: Day 3

  34. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group

    Patient's declaration in the Thess Monitoring Application

    Time frame: Day 4

  35. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group

    Phone call from the patient

    Time frame: Day 4

  36. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group

    Patient's declaration in the Thess Monitoring Application

    Time frame: Day 5

  37. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group

    Phone call from the patient

    Time frame: Day 5

  38. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group

    Patient's declaration in the Thess Monitoring Application

    Time frame: Day 6

  39. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group

    Phone call from the patient

    Time frame: Day 6

  40. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the experimental group

    Patient's declaration in the Thess Monitoring Application

    Time frame: Day 7

  41. Rate of adherence to the standard pain management regimen (non-opioid analgesics) in the standard care (control) group

    Phone call from the patient

    Time frame: Day 7

  42. Incidence of adverse effects associated with opioid use in the experimental group

    Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Baseline

  43. Incidence of adverse effects associated with opioid use in the standard care (control) group

    Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Baseline

  44. Incidence of adverse effects associated with opioid use in the experimental group

    Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 1

  45. Incidence of adverse effects associated with opioid use in the standard care (control) group

    Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 1

  46. Incidence of adverse effects associated with opioid use in the experimental group

    Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 2

  47. Incidence of adverse effects associated with opioid use in the standard care (control) group

    Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 2

  48. Incidence of adverse effects associated with opioid use in the experimental group

    Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 3

  49. Incidence of adverse effects associated with opioid use in the standard care (control) group

    Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 3

  50. Incidence of adverse effects associated with opioid use in the experimental group

    Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 4

  51. Incidence of adverse effects associated with opioid use in the standard care (control) group

    Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 4

  52. Incidence of adverse effects associated with opioid use in the experimental group

    Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 5

  53. Incidence of adverse effects associated with opioid use in the standard care (control) group

    Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 5

  54. Incidence of adverse effects associated with opioid use in the experimental group

    Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 6

  55. Incidence of adverse effects associated with opioid use in the standard care (control) group

    Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 6

  56. Incidence of adverse effects associated with opioid use in the experimental group

    Adverse effects associated with opioid use will be recorded on the Thess Monitoring Application Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 7

  57. Incidence of adverse effects associated with opioid use in the standard care (control) group

    Adverse effects associated with opioid use will be recorded via a phone call to the patient Nausea: yes/no Drowsiness: yes/no Dizziness: yes/no Itching: yes/no

    Time frame: Day 7

  58. Adverse Events [Safety and Tolerability] in the experimental group

    Qualitative assessment. Any adverse events of any cause related to treatment will be recorded in the electronic clinical registration form following a phone call to the patient.

    Time frame: Day 7

  59. Adverse Events [Safety and Tolerability]in the standard care (control) group

    Qualitative assessment. Any adverse events of any cause related to treatment will be recorded in the electronic clinical registration form following a phone call to the patient.

    Time frame: Day 7

  60. Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application

    Time frame: Day 1

  61. Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form

    Time frame: Day 1

  62. Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application

    Time frame: Day 2

  63. Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical monitoring form

    Time frame: Day 2

  64. Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application

    Time frame: Day 3

  65. Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form

    Time frame: Day 3

  66. Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application

    Time frame: Day 4

  67. Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form

    Time frame: Day 4

  68. Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application

    Time frame: Day 5

  69. Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form

    Time frame: Day 5

  70. Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application

    Time frame: Day 6

  71. Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form

    Time frame: Day 6

  72. Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application

    Time frame: Day 7

  73. Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical monitoring form

    Time frame: Day 7

  74. Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application and a phone call to the patient

    Time frame: Month 1

  75. Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form and a phone call to the patient

    Time frame: Month 1

  76. Use of medication (including opioid medications and treatments outside the standard regimen) in the experimental group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection via the Tess Monitoring Application and a phone call to the patient

    Time frame: Month 3

  77. Use of medication (including opioid medications and treatments outside the standard regimen) in the standard care (control) group

    Collection of data on treatments prescribed outside the standard regimen and prescriptions issued on discharge from hospital up to three months of follow-up. Data collection on the electronic clinical registration form and a phone call to the patient

    Time frame: Month 3

  78. Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group

    Data collection via the Tess Monitoring Application

    Time frame: Day 1

  79. Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group

    Data collection on the electronic clinical registration form

    Time frame: Day 1

  80. Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group

    Data collection via the Tess Monitoring Application

    Time frame: Day 2

  81. Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group

    Data collection on the electronic clinical registration form

    Time frame: Day 2

  82. Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group

    Data collection via the Tess Monitoring Application

    Time frame: Day 3

  83. Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group

    Data collection on the electronic clinical registration form

    Time frame: Day 3

  84. Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the experimental group

    Data collection via the Tess Monitoring Application

    Time frame: Day 4

  85. Number of unplanned medical appointments and telephone contacts with healthcare professionals after discharge from hospital in the standard care (control) group

    Data collection on the electronic clinical registration form

    Time frame: Day 4

  86. Prescription issued outside of those prescribed upon hospital discharge in the experimental group

    Quantitative

    Time frame: Month 3

  87. Prescription issued outside of those prescribed upon hospital discharge in the standard care(control) group

    Quantitative

    Time frame: Month 3

  88. Number of days of sick leave prescribed in the experimental group

    Quantitative

    Time frame: Month 3

  89. Number of days of sick leave prescribed in the standard care (control) group

    Quantitative

    Time frame: Month 3

  90. Satisfaction questionnaire administered to the patient in the experimental group

    Qualitative

    Time frame: Day 3

  91. Satisfaction questionnaire administered to the patient in the standard care (control) group

    Qualitative

    Time frame: Day 3

  92. Satisfaction questionnaire administered to the anesthesiologist in the experimental group

    Qualitative

    Time frame: End of the inclusion period

  93. Satisfaction questionnaire administered to the anesthesiologist in the standard care (control) group

    Qualitative

    Time frame: End of the inclusion period

  94. System Usability Scale score during the follow-up call to patients in the experimental group

    The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.

    Time frame: Day 30

  95. System Usability Scale score from health providers to the experimental group

    The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.

    Time frame: End of the inclusion period

  96. System Usability Scale score during the follow-up call to patients in the standard care (control) group

    The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.

    Time frame: Day 30

  97. System Usability Scale score from health providers to the standard care (control) group

    The System Usability Scale (SUS) score is a measure of the usability of an interactive system, derived from a questionnaire that includes ten items. Each item is presented as a positive statement, and users are asked to indicate their agreement or disagreement with it using a 5-point Likert scale. The score is recalculated based on the number of items answered correctly, with a score of 2.5 for each item. This scoring system allows the assessment of user satisfaction and the overall usability of the system.

    Time frame: End of the inclusion period

  98. DN2 questionnaire score in the experimental group

    The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.

    Time frame: Post-operative Month 1

  99. DN2 questionnaire score in the experimental group

    The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.

    Time frame: Post-operative Month 2

  100. DN2 questionnaire score in the experimental group

    The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.

    Time frame: Post-operative Month 3

  101. DN2 questionnaire score in the standard care (control) group

    The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.

    Time frame: Post-operative Month 1

  102. DN2 questionnaire score in the standard care (control) group

    The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.

    Time frame: Post-operative Month 2

  103. DN2 questionnaire score in the standard care (control) group

    The DN2 questionnaire is a simplified version of the DN4 (omitting the clinical examination), developed in France in 2005 by Bouhassira and the French Neuropathic Pain Group. It consists of two questions assessing the presence or absence of seven symptoms suggestive of neuropathic pain : burning, painful cold, electric shocks, tingling, prickling, numbness, and itching. The cutoff for a positive DN2 result is set at 3 out of 7 points. A positive DN2 result does not establish a formal diagnosis of neuropathic pain, as a clinical examination remains essential.

    Time frame: Post-operative Month 3

  104. Rate of incidents, malfunctions, and organization deviations that occurred during implementation in the experimental group

    Qualitative

    Time frame: Month 3

  105. Time spent connected to the Thess Monitoring device per patient in the experimental group

    Quantitative, in minutes

    Time frame: Month 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Allvin R, Berg K, Idvall E, Nilsson U. Postoperative recovery: a concept analysis. J Adv Nurs. 2007 Mar;57(5):552-8. doi: 10.1111/j.1365-2648.2006.04156.x. PubMed 17284272 ↗
  • Althaus A, Hinrichs-Rocker A, Chapman R, Arranz Becker O, Lefering R, Simanski C, Weber F, Moser KH, Joppich R, Trojan S, Gutzeit N, Neugebauer E. Development of a risk index for the prediction of chronic post-surgical pain. Eur J Pain. 2012 Jul;16(6):901-10. doi: 10.1002/j.1532-2149.2011.00090.x. Epub 2011 Dec 23. PubMed 22337572 ↗
  • Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg. 2003 Aug;97(2):534-540. doi: 10.1213/01.ANE.0000068822.10113.9E. PubMed 12873949 ↗
  • Atkins RM, Duckworth T, Kanis JA. Algodystrophy following Colles' fracture. J Hand Surg Br. 1989 May;14(2):161-4. doi: 10.1016/0266-7681_89_90118-6. PubMed 2746114 ↗
  • Attal N, Lanteri-Minet M, Laurent B, Fermanian J, Bouhassira D. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain. 2011 Dec;152(12):2836-2843. doi: 10.1016/j.pain.2011.09.014. Epub 2011 Oct 20. PubMed 22019149 ↗
  • Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002 Feb;52(2):69-77. doi: 10.1016/s0022-3999(01)00296-3. PubMed 11832252 ↗
  • Bonnet A, Lavand'homme P, France MN, Reding R, De Kock M. [Postoperative pain trajectories to identify risk of chronic postsurgical pain in living donors for liver transplantation]. Ann Fr Anesth Reanim. 2012 Dec;31(12):945-9. doi: 10.1016/j.annfar.2012.09.011. Epub 2012 Oct 30. French. PubMed 23117039 ↗
  • Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lanteri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005 Mar;114(1-2):29-36. doi: 10.1016/j.pain.2004.12.010. Epub 2005 Jan 26. PubMed 15733628 ↗
  • Chapman CR, Donaldson G, Davis J, Ericson D, Billharz J. Postoperative pain patterns in chronic pain patients: a pilot study. Pain Med. 2009 Apr;10(3):481-7. doi: 10.1111/j.1526-4637.2008.00522.x. Epub 2008 Nov 5. PubMed 18992044 ↗
  • Chapman CR, Davis J, Donaldson GW, Naylor J, Winchester D. Postoperative pain trajectories in chronic pain patients undergoing surgery: the effects of chronic opioid pharmacotherapy on acute pain. J Pain. 2011 Dec;12(12):1240-6. doi: 10.1016/j.jpain.2011.07.005. Epub 2011 Oct 26. PubMed 22036517 ↗
  • Chaves JF, Brown JM. Spontaneous cognitive strategies for the control of clinical pain and stress. J Behav Med. 1987 Jun;10(3):263-76. doi: 10.1007/BF00846540. PubMed 3612783 ↗
  • Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, Carter T, Cassidy CL, Chittenden EH, Degenhardt E, Griffith S, Manworren R, McCarberg B, Montgomery R, Murphy J, Perkal MF, Suresh S, Sluka K, Strassels S, Thirlby R, Viscusi E, Walco GA, Warner L, Weisman SJ, Wu CL. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. J Pain. 2016 Feb;17(2):131-57. doi: 10.1016/j.jpain.2015.12.008. PubMed 26827847 ↗
  • de Mos M, de Bruijn AG, Huygen FJ, Dieleman JP, Stricker BH, Sturkenboom MC. The incidence of complex regional pain syndrome: a population-based study. Pain. 2007 May;129(1-2):12-20. doi: 10.1016/j.pain.2006.09.008. Epub 2006 Nov 7. PubMed 17084977 ↗
  • Demumieux F, Ludes PO, Diemunsch P, Bennett-Guerrero E, Lujic M, Lefebvre F, Noll E. Validation of the translated Quality of Recovery-15 questionnaire in a French-speaking population. Br J Anaesth. 2020 Jun;124(6):761-767. doi: 10.1016/j.bja.2020.03.011. Epub 2020 Apr 15. PubMed 32303379 ↗
  • Duale C, Ouchchane L, Schoeffler P; EDONIS Investigating Group; Dubray C. Neuropathic aspects of persistent postsurgical pain: a French multicenter survey with a 6-month prospective follow-up. J Pain. 2014 Jan;15(1):24.e1-24.e20. doi: 10.1016/j.jpain.2013.08.014. Epub 2013 Oct 25. PubMed 24373573 ↗
  • Harden NR, Bruehl S, Stanos S, Brander V, Chung OY, Saltz S, Adams A, Stulberg DS. Prospective examination of pain-related and psychological predictors of CRPS-like phenomena following total knee arthroplasty: a preliminary study. Pain. 2003 Dec;106(3):393-400. doi: 10.1016/j.pain.2003.08.009. PubMed 14659522 ↗
  • Herrmann C. International experiences with the Hospital Anxiety and Depression Scale--a review of validation data and clinical results. J Psychosom Res. 1997 Jan;42(1):17-41. doi: 10.1016/s0022-3999(96)00216-4. PubMed 9055211 ↗
  • Hinrichs-Rocker A, Schulz K, Jarvinen I, Lefering R, Simanski C, Neugebauer EA. Psychosocial predictors and correlates for chronic post-surgical pain (CPSP) - a systematic review. Eur J Pain. 2009 Aug;13(7):719-30. doi: 10.1016/j.ejpain.2008.07.015. Epub 2008 Oct 25. PubMed 18952472 ↗
  • Johansen A, Romundstad L, Nielsen CS, Schirmer H, Stubhaug A. Persistent postsurgical pain in a general population: prevalence and predictors in the Tromso study. Pain. 2012 Jul;153(7):1390-1396. doi: 10.1016/j.pain.2012.02.018. Epub 2012 Mar 24. PubMed 22445291 ↗
  • Kehlet H. Surgical stress: the role of pain and analgesia. Br J Anaesth. 1989 Aug;63(2):189-95. doi: 10.1093/bja/63.2.189. No abstract available. PubMed 2669908 ↗
  • Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006 May 13;367(9522):1618-25. doi: 10.1016/S0140-6736(06)68700-X. PubMed 16698416 ↗
  • Krakowski I, Theobald S, Balp L, Bonnefoi MP, Chvetzoff G, Collard O, Collin E, Couturier M, Delorme T, Duclos R, Eschalier A, Fergane B, Larue F, Magnet M, Minello C, Navez ML, Richard A, Richard B, Rostaing-Rigattieri S, Rousselot H, Santolaria N, Torloting G, Toussaint S, Vuillemin N, Wagner JP, Fabre N; FNCLCC. Summary version of the Standards, Options and Recommendations for the use of analgesia for the treatment of nociceptive pain in adults with cancer (update 2002). Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S67-72. doi: 10.1038/sj.bjc.6601086. No abstract available. PubMed 12915905 ↗
  • Lavand'homme P. The progression from acute to chronic pain. Curr Opin Anaesthesiol. 2011 Oct;24(5):545-50. doi: 10.1097/ACO.0b013e32834a4f74. PubMed 21772141 ↗
  • Lavand'homme PM, Grosu I, France MN, Thienpont E. Pain trajectories identify patients at risk of persistent pain after knee arthroplasty: an observational study. Clin Orthop Relat Res. 2014 May;472(5):1409-15. doi: 10.1007/s11999-013-3389-5. PubMed 24258688 ↗
  • Lepine JP, Godchau M, Brun P, Lemperiere T. [Evaluation of anxiety and depression among patients hospitalized on an internal medicine service]. Ann Med Psychol (Paris). 1985 Feb;143(2):175-89. No abstract available. French. PubMed 4037594 ↗
  • Tsui SL, Law S, Fok M, Lo JR, Ho E, Yang J, Wong J. Postoperative analgesia reduces mortality and morbidity after esophagectomy. Am J Surg. 1997 Jun;173(6):472-8. doi: 10.1016/s0002-9610(97)00014-7. PubMed 9207157 ↗
  • Maguire MF, Latter JA, Mahajan R, Beggs FD, Duffy JP. A study exploring the role of intercostal nerve damage in chronic pain after thoracic surgery. Eur J Cardiothorac Surg. 2006 Jun;29(6):873-9. doi: 10.1016/j.ejcts.2006.03.031. Epub 2006 May 3. PubMed 16675262 ↗
  • Martinez V, Baudic S, Fletcher D. [Chronic postsurgical pain]. Ann Fr Anesth Reanim. 2013 Jun;32(6):422-35. doi: 10.1016/j.annfar.2013.04.012. Epub 2013 Jun 7. French. PubMed 23747211 ↗
  • Monk TG, Saini V, Weldon BC, Sigl JC. Anesthetic management and one-year mortality after noncardiac surgery. Anesth Analg. 2005 Jan;100(1):4-10. doi: 10.1213/01.ANE.0000147519.82841.5E. PubMed 15616043 ↗
  • Myles PS, Hunt JO, Fletcher H, Solly R, Woodward D, Kelly S. Relation between quality of recovery in hospital and quality of life at 3 months after cardiac surgery. Anesthesiology. 2001 Oct;95(4):862-7. doi: 10.1097/00000542-200110000-00013. PubMed 11605925 ↗
  • Myles PS, Weitkamp B, Jones K, Melick J, Hensen S. Validity and reliability of a postoperative quality of recovery score: the QoR-40. Br J Anaesth. 2000 Jan;84(1):11-5. doi: 10.1093/oxfordjournals.bja.a013366. PubMed 10740540 ↗
  • Myles PS, Myles DB. An Updated Minimal Clinically Important Difference for the QoR-15 Scale. Anesthesiology. 2021 Nov 1;135(5):934-935. doi: 10.1097/ALN.0000000000003977. No abstract available. PubMed 34543410 ↗
  • Myles PS, Shulman MA, Reilly J, Kasza J, Romero L. Measurement of quality of recovery after surgery using the 15-item quality of recovery scale: a systematic review and meta-analysis. Br J Anaesth. 2022 Jun;128(6):1029-1039. doi: 10.1016/j.bja.2022.03.009. Epub 2022 Apr 14. PubMed 35430086 ↗
  • Parsons B, Schaefer C, Mann R, Sadosky A, Daniel S, Nalamachu S, Stacey BR, Nieshoff EC, Tuchman M, Anschel A. Economic and humanistic burden of post-trauma and post-surgical neuropathic pain among adults in the United States. J Pain Res. 2013 Jun 17;6:459-69. doi: 10.2147/JPR.S44939. Print 2013. PubMed 23825931 ↗
  • Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology. 2000 Oct;93(4):1123-33. doi: 10.1097/00000542-200010000-00038. No abstract available. PubMed 11020770 ↗
  • Rawal N, Berggren L. Organization of acute pain services: a low-cost model. Pain. 1994 Apr;57(1):117-123. doi: 10.1016/0304-3959(94)90115-5. PubMed 8065788 ↗
  • Rodgers A, Walker N, Schug S, McKee A, Kehlet H, van Zundert A, Sage D, Futter M, Saville G, Clark T, MacMahon S. Reduction of postoperative mortality and morbidity with epidural or spinal anaesthesia: results from overview of randomised trials. BMJ. 2000 Dec 16;321(7275):1493. doi: 10.1136/bmj.321.7275.1493. PubMed 11118174 ↗
  • Rosenstiel AK, Keefe FJ. The use of coping strategies in chronic low back pain patients: relationship to patient characteristics and current adjustment. Pain. 1983 Sep;17(1):33-44. doi: 10.1016/0304-3959(83)90125-2. PubMed 6226916 ↗
  • Rothaug J, Zaslansky R, Schwenkglenks M, Komann M, Allvin R, Backstrom R, Brill S, Buchholz I, Engel C, Fletcher D, Fodor L, Funk P, Gerbershagen HJ, Gordon DB, Konrad C, Kopf A, Leykin Y, Pogatzki-Zahn E, Puig M, Rawal N, Taylor RS, Ullrich K, Volk T, Yahiaoui-Doktor M, Meissner W. Patients' perception of postoperative pain management: validation of the International Pain Outcomes (IPO) questionnaire. J Pain. 2013 Nov;14(11):1361-70. doi: 10.1016/j.jpain.2013.05.016. Epub 2013 Sep 7. PubMed 24021577 ↗
  • Smith WC, Bourne D, Squair J, Phillips DO, Chambers WA. A retrospective cohort study of post mastectomy pain syndrome. Pain. 1999 Oct;83(1):91-5. doi: 10.1016/s0304-3959(99)00076-7. PubMed 10506676 ↗
  • Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003 Aug 1;1:29. doi: 10.1186/1477-7525-1-29. PubMed 12914662 ↗
  • Snaith RP, Zigmond AS. The hospital anxiety and depression scale. Br Med J (Clin Res Ed). 1986 Feb 1;292(6516):344. doi: 10.1136/bmj.292.6516.344. No abstract available. PubMed 3080166 ↗
  • Stark PA, Myles PS, Burke JA. Development and psychometric evaluation of a postoperative quality of recovery score: the QoR-15. Anesthesiology. 2013 Jun;118(6):1332-40. doi: 10.1097/ALN.0b013e318289b84b. PubMed 23411725 ↗
  • Untas A, Aguirrezabal M, Chauveau P, Leguen E, Combe C, Rascle N. [Anxiety and depression in hemodialysis: validation of the Hospital Anxiety and Depression Scale (HADS)]. Nephrol Ther. 2009 Jun;5(3):193-200. doi: 10.1016/j.nephro.2009.01.007. Epub 2009 Apr 5. French. PubMed 19346177 ↗
  • VanDenKerkhof EG, Hopman WM, Goldstein DH, Wilson RA, Towheed TE, Lam M, Harrison MB, Reitsma ML, Johnston SL, Medd JD, Gilron I. Impact of perioperative pain intensity, pain qualities, and opioid use on chronic pain after surgery: a prospective cohort study. Reg Anesth Pain Med. 2012 Jan-Feb;37(1):19-27. doi: 10.1097/AAP.0b013e318237516e. PubMed 22157741 ↗
  • Woolf CJ. Generation of acute pain: central mechanisms. Br Med Bull. 1991 Jul;47(3):523-33. doi: 10.1093/oxfordjournals.bmb.a072490. PubMed 1794070 ↗
  • Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70. doi: 10.1111/j.1600-0447.1983.tb09716.x. PubMed 6880820 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Aug 2026, 8 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 8 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Aug 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07680998
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Dec 1, 2025
Primary completion
Aug 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jul 8, 2026

Study contacts

Joël LHERMITE, Dr.
Contact
joel.lhermite@chu-nimes.fr
+334.66.68.30.50
Anissa MEGZARI
Contact
drc@chu-nimes.fr
0466684236

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion